Electrogenics Laboratories Limited’s cover photo
Electrogenics Laboratories Limited

Electrogenics Laboratories Limited

Medical Equipment Manufacturing

North Sydney, NSW 172 followers

SAFER RADIOTHERAPY FOR CANCER, ANGIOGRAMS & DIAGNOSTIC (CT) SCANS. A NEW REVOLUTIONARY REAL-TIME RADIATION SENSOR TECH

About us

The next generation MOSkin dosimeter is the only medical radiation sensor technology in the world that accurately measures individual radiation doses and dose rates, in real time, at precisely defined and reproducible skin tissue and organ depth for the global $35 billion radiotherapy for cancer treatment, angiography equipment and CT and Xray scan markets. Electrogenics Laboratories Ltd (ELL), was formed in 2019 to commercialise this breakthrough, patented technology developed by the Centre for Medical Radiation Physics (CMRP), University of Wollongong (UOW), Australia. It has been fully tested and proven with over $8 million of grant funding in over 20 hospitals and clinics including Australia, Brazil, Italy, Malaysia and China. The ELL senior management and support staff team provide extensive experience in advanced technology product development and international business development to rapidly drive MOSkin to full global commercialisation and distribution. Distinguished Professor Anatoly Rozenfeld, Professor Michael Lerch, and Associate Professor Marco Petasecca from UOW are ELL’s scientific advisors. Australian development partners including Genesys Electronics Design and Design & Industry. ELL’s goal is to become the world leader in the development and provision of cutting edge, next generation radiation dosimetry solutions. T

Industry
Medical Equipment Manufacturing
Company size
2-10 employees
Headquarters
North Sydney, NSW
Type
Public Company
Founded
2019

Locations

Employees at Electrogenics Laboratories Limited

Updates

  • Electrogenics Laboratories Limited reposted this

    The UOW developed, world-first radiation dosimetry tool MOSkinTM has received a further $1m in funding from the Australian Government as it continues its path towards commercialisation. 👏 Similar to a sticker or label, MOSkinTM is a small, adhesive panel, that, when placed on the skin at the site of radiotherapy treatment, can accurately measure the amount of radiation the skin receives and hence reduce the potential for unwanted side effects, such as skin burns and damage to surrounding tissues. MOSkinTM is being brought to market through a partnership with Electrogenics Laboratories Limited, who are manufacturing and hold the global licence to the device. Professor Anatoly Rozenfeld has been developing MOSkinTM with his team for many years and said it is rewarding to know that the device will provide confidence in radiotherapy treatment and better outcomes for quality of life for patients. “More than 50 per cent of patients who receive a cancer diagnosis will be treated with radiotherapy and yet until this device was developed, there was no accurate way to measure skin dosage at the site of treatment and provide clinical data during or immediately after treatment." #UOWResearch #ThisIsUOW

    • No alternative text description for this image

Similar pages

Browse jobs